The Dose Adjustment for Normal Eating (DAFNE) course is a structured education programme that aims to teach individuals with Type 1 diabetes to change their self-care behaviours by
estimating the carbohydrate content of food and adjusting their insulin doses accordingly in order to maintain acceptable metabolic control. DAFNE has been found to improve quality of life
and glycosylated haemoglobin (HbA1c) levels in UK Type 1 diabetes patients1 and a cost-effectiveness modelling analysis concluded that DAFNE was cost-effective and would pay for itself
within four years2
. As with the majority of other economic models in Type 1 diabetes, this analysis had a clinical rather than behavioural focus. The progression of diabetes and its
complications was modelled, with clinical and sociodemographic factors as the model inputs, to predict costs and quality-adjusted life years (QALYs) based on the long-term incidence of
diabetic complications.
Despite positive clinical and cost-effectiveness outcomes from DAFNE there is variability in how patients respond, with some patients continuing to experience problems with high HbA1c
levels or frequent hypoglycaemia after receiving the intervention. There is currently no method for predicting how an individual patient will respond to the DAFNE course.
As part of a national DAFNE research team we are developing a new economic model of Type 1 diabetes that incorporates psychosocial and behavioural patient characteristics as predictive
variables. Our study aims to account for heterogeneity in patient response to DAFNE within the model and investigate how predictions can be made prior to or shortly after the DAFNE
course about how a patient’s metabolic control will be affected by the intervention.
History
Ethics
There is no personal data or any that requires ethical approval
Policy
The data complies with the institution and funders' policies on access and sharing